Heart failure & cardiomyopathies
Transthyretin Cardiac Amyloid: Broad Heart Failure Phenotypic Spectrum and Implications for Diagnosis
Authors' conclusion
Although ATTR-CA is traditionally thought to be seen primarily among patients with HFpEF, our data suggest that ATTR-CA has a higher prevalence among patients with HFrEF
Study context
- Population
- Consecutive patients with transthyretin cardiac amyloidosis (ATTR-CA), single centre, February 2016–December 2022 (age 78.1 ± 8.6 years, 91.1% male)
- Participants
- 46 / 38 / 129
- Exposure
- Heart failure (HF) phenotypes at ATTR-CA diagnosis
- Heart failure with reduced ejection fraction (HFrEF)n = 46
- Heart failure with mildly reduced ejection fraction (HFmrEF)n = 38
- Heart failure with preserved ejection fraction (HFpEF)n = 129reference
- Outcome
- Prevalence of HF phenotypes at ATTR-CA diagnosis
- Follow-up
- At the time of ATTR-CA diagnosis
Methodological detailssingle-centre, consecutive patients
- Single-centre
- Consecutive patients
Main finding
As reported in the abstract
HF phenotype at ATTR-CA diagnosis
Observational data: associations, not effects.
Further findings
Clinical characteristics, HFrEF or HFmrEF vs HFpEF
- HFrEF or HFmrEF more likely African American, with significantly worse New York Heart Association (NYHA) class, higher N-terminal pro-brain natriuretic peptide (NT-proBNP) and higher serum creatinine vs HFpEF
Original publication
Transthyretin Cardiac Amyloid: Broad Heart Failure Phenotypic Spectrum and Implications for Diagnosis. ESC Heart Fail. Published 24 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →